Healthcare Industry News: p53
News Release - July 8, 2008
Gemin X Pharmaceuticals Appoints Peter R. Dolan to Board of DirectorsMALVERN, Pa. & MONTREAL--(HSMN NewsFeed)--Gemin X Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel treatments for cancer, announced the appointment of Peter R. Dolan to its Board of Directors.
“We are extremely pleased to have Peter join our Board,” said Dr. Robert G. McNeil, founding Managing Director of Sanderling Ventures and Chairman of Gemin X. “Peter brings a wealth of experience in running a global pharmaceutical company, having served in numerous leadership positions at Bristol-Myers Squibb, most recently as CEO for more than five years.”
Mr. Timothy J. Barberich, Chairman of Sepracor, Inc. and a Gemin X Director, added, “The strength and caliber of Peter’s business and operational knowledge as well as his insight into the industry will be extremely valuable as our novel oncology therapeutics advance towards later-stage clinical development and ultimately, commercialization.”
Peter Dolan served as chief executive officer of Bristol-Myers Squibb from 2001 to 2006. He joined Bristol-Myers Squibb in 1988 in the over-the-counter consumer products division and subsequently held senior management positions in the company’s various businesses, including pharmaceuticals, medical devices, consumer and medical nutritionals and consumer medicines. Mr. Dolan became president of the company and a member of its board of directors in January 2000, and served as chairman of the board from 2001-2005.
Mr. Dolan is currently a trustee of Tufts University, where he chairs the Administration and Finance Committee and serves on the Executive, Audit and Compensation Committees. He is a member of the board of overseers of the Tuck School at Dartmouth College. Additionally, he is also a member of the board of directors of the National Centre on Addiction and Substance Abuse at Columbia University and a member of the Business Council. He served on the boards of the American Express Company, C-Change (a cancer coalition organization), and was chairman of the Pharmaceutical Research and Manufacturers’ Association of America.
Mr. Dolan holds a B.A. from Tufts University and an M.B.A. from the Tuck School of Business at Dartmouth.
About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), a small molecule, pan Bcl-2 inhibitor, is currently in Phase 2 clinical trials in both hematological and solid tumor cancers. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in a Phase 1 clinical trial in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montreal, Canada. www.geminx.com
Source: Gemin X Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.